CRISPR Therapeutics announced a new gene‑editing tool it described as a “significant advance” over prime editing, setting off a public disagreement with Prime Medicine, which challenged the claim. The exchange highlights intensifying competition and messaging battles among leading gene‑editing firms as they vie for scientific leadership and investor confidence. Both companies have been advancing next‑generation editing technologies aimed at improving precision and minimizing off‑target effects. CRISPR’s announcement focused on improved capabilities; Prime Medicine countered that the claim overstates comparative advantages and cautioned against premature commercial assertions. The spat underscores how quickly narrative control over platform advances can affect partnerships, valuations and recruitment of translational collaborators in gene therapy and somatic editing.